About Intradigm Corporation
Intradigm Corporation is a company based in Palo Alto (United States) founded in 2000 was acquired by Silence Therapeutics in December 2009. Intradigm Corporation has raised $37.4 million across 2 funding rounds from investors including Roche, Novartis and Silence Therapeutics. Intradigm Corporation operates in a competitive market with competitors including Jazz Pharmaceuticals, Denali Therapeutics, C4 Therapeutics, Erasca and Revolution Medicines, among others.
- Headquarter Palo Alto, United States
-
Sectors
HealthcareTechnology
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Intradigm Corporation
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$37.4 M (USD)
in 2 rounds
-
Latest Funding Round
$21.4 M (USD), Series B
Jan 07, 2009
-
Investors
Roche
& 10 more
-
Employee Count
Not available
-
Acquired by
Silence Therapeutics
(Dec 16, 2009)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Funding Insights of Intradigm Corporation
Intradigm Corporation has successfully raised a total of $37.4M across 2 strategic funding rounds. The most recent funding activity was a Series B round of $21.4 million completed in January 2009. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Intradigm Corporation
Intradigm Corporation has secured backing from 11 investors, including venture fund and institutional investors. Prominent investors backing the company include Roche, Novartis and Silence Therapeutics.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
A venture capital firm focused on life science innovations.
|
Locked | Locked | Locked | |
|
Healthcare sector private equity investments are managed by the firm.
|
Locked | Locked | Locked | |
|
-
|
Locked | Locked | Locked |
Investor details for Intradigm Corporation
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Intradigm Corporation
Investment portfolio details for Intradigm Corporation
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Intradigm Corporation
Detailed financials for Intradigm Corporation
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Intradigm Corporation Comparisons
Peer comparison for Intradigm Corporation
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Intradigm Corporation
Intradigm Corporation operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Jazz Pharmaceuticals, Denali Therapeutics, C4 Therapeutics, Erasca and Revolution Medicines, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Novel biopharmaceutical medicines are developed for unmet medical needs.
|
|
| Locked | Locked | Locked |
Neurodegenerative disease therapies are developed for Alzheimer's, ALS, and Parkinson's.
|
|
| Locked | Locked | Locked |
Small-molecule drugs for cancer treatment are developed via Degronimid platform.
|
|
| Locked | Locked | Locked |
Small molecule therapeutics for cancer treatment are developed.
|
|
| Locked | Locked | Locked |
Cancer therapies are developed using selective pathway inhibitors.
|
|
| Locked | Locked | Locked |
MicroRNA-based therapeutics are developed for treating multiple diseases.
|
Detailed competitors of Intradigm Corporation
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Intradigm Corporation
Complete news archive for Intradigm Corporation
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Intradigm Corporation
Intradigm Corporation was founded in 2000 and raised its 1st funding round 6 years after it was founded.
Intradigm Corporation is headquartered in Palo Alto, United States. It is registered at Palo Alto, California, United States.
Intradigm Corporation is a funded company, having raised a total of $37.4M across 2 funding rounds to date.
Intradigm Corporation was founded in 2000 and is based in Palo Alto, United States. Focus is placed on the biotechnology sector, where RNA interference therapeutics are developed for serious diseases, starting with oncology. Operations involve the use of proprietary Nanoplex delivery technology, which allows targeted administration to specific tissues via systemic drug delivery methods.
Intradigm Corporation's top competitors include Jazz Pharmaceuticals, C4 Therapeutics and Erasca.
Intradigm Corporation has 11 investors. Key investors include Roche, Novartis, Silence Therapeutics, Genentech, and Frazier Healthcare Partners.